TY - JOUR T1 - Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting JO - Reumatología Clínica T2 - AU - Marsal Barril,Sara AU - Martin-Martinez,Mª Auxiliadora AU - Blanco-Garcia,Francisco Javier AU - Fernández-Nebro,Antonio AU - García de Vicuña,Rosario AU - Tornero-Molina,Jesús AU - Sánchez-Alonso,Fernando AU - Novella-Navarro,Marta AU - Escudero-Contreras,Alejandro AU - Alegre-Sancho,Juan José AU - Urruticoechea-Arana,Ana AU - Bustabad-Reyes,Maria Sagrario AU - Trenor-Larraz,Pilar AU - Pérez-Sandoval,Trinidad AU - Tevar-Sánchez,Maria Isabel AU - Sánchez-Costa,Jesús T. AU - Raya-Álvarez,Enrique SN - 1699258X M3 - 10.1016/j.reuma.2021.12.001 DO - 10.1016/j.reuma.2021.12.001 UR - https://www.reumatologiaclinica.org/es-effectiveness-safety-tocilizumab-in-monotherapy-articulo-S1699258X21002783 AB - ObjectiveTo evaluate the effectiveness and safety of tocilizumab (TCZ) monotherapy in biologic-naïve patients with rheumatoid arthritis (RA) versus patients with previous biologic exposure in a real-world setting. Materials and methodsNon-controlled clinical-trial, 32-week prospective multicenter study including RA patients with moderate-severe disease activity starting TCZ in monotherapy who had a prior inadequate response or were intolerant to methotrexate (MTX). Effectiveness according to EULAR response evaluated at 24-week and safety at 32-weekwere assessed. ResultsOf the 93 were enrolled of whom 84 (90%) were eligible for the effectiveness analysis. Biologic-naïve patients (n=46, 54.8%) were younger (51.5 versus 57.9) with shorter disease duration (6.4 versus 13.3) but presented similar comorbidities in comparison with non-naïve patients. DAS28 remission was achieved in a higher percentage in the group of patients with prior biological treatment. 89 adverse events (AE) were recorded in 50 patients, most of them non-serious AE (non-SAE) (86.3%). ConclusionsIn a real world setting, TCZ exhibit similar effectiveness and safety in monotherapy in patients with RA regardless previous exposure to other biologic therapies. This study provides additional and valuable real-world findings on the use of TCZ in patients with RA. ER -